The correlation between the plasma concentration of gemcitabine and short-term efficacy and adverse reactions in patients with advanced squamous cell carcinoma of the lung using liquid chromatography-mass spectrometry
Conclusions: In patients with advanced non-small cell lung cancer, a high plasma concentration of gemcitabine can improve the short-term clinical efficacy of treatment, but increase the incidence of grade III-IV adverse reactions. [Ethiop. J. Health Dev. 2021; 35(1):72-82]Key words: Non-small cell lung cancer, gemcitabine, plasma concentration, short-term efficacy, adverse reactions
Source: Ethiopian Journal of Health Development - Category: African Health Authors: Xi Jia-xi , Zhang Hua-jun, Chen Xiao-yu, Ye Dong-mei, Lan Bi-quan, Chen Ying, Su Heng-hai Source Type: research
More News: African Health | Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Ethiopia Health | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Thrombocytopenia | Urology & Nephrology